
GMAB Stock Forecast & Price Target
GMAB Analyst Ratings
Bulls say
Genmab has demonstrated a strong financial position, ending the third quarter of 2025 with approximately $3.4 billion in cash, cash equivalents, and marketable securities, which provides a solid foundation for ongoing operations and R&D investment. The latest reported sales for DARZALEX exceeded prior estimates, with 4Q25 royalties projected to reach $722 million, reflecting strong demand and a 40% reduction in risk of progression compared to earlier treatments. With its robust pipeline of therapeutics and a history of profitability, Genmab is well-positioned to navigate the challenging biotech sector while potentially delivering multiple near- and medium-term clinical data catalysts.
Bears say
Genmab's stock outlook is negatively impacted by several key risks, primarily the slowing sales of its leading product, Darzalex, along with the potential failure to secure label extensions for this therapy. The recent failure of Epcoritamab (Epkinly) in clinical trials to demonstrate a significant improvement in overall survival has led to decreased expectations for its approval timeline, which has been revised downward. Furthermore, there are concerns regarding the company's ability to penetrate markets with other therapies, the risk of dilution, and broader macroeconomic factors that could adversely affect financial performance.
This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.
GMAB Analyst Forecast & Price Prediction
Start investing in GMAB
Order type
Buy in
Order amount
Est. shares
0 shares